|1.||Renwick, Andrew: 1 article (01/2010)|
|2.||Smoot, Dustin L: 1 article (01/2010)|
|3.||Leblanc, Jean-Charles: 1 article (01/2010)|
|4.||Setzer, R Woodrow: 1 article (01/2010)|
|5.||Zielinski, Martin D: 1 article (01/2010)|
|6.||Cullinane, Daniel C: 1 article (01/2010)|
|7.||Jenkins, Donald H: 1 article (01/2010)|
|8.||Sawyer, Mark D: 1 article (01/2010)|
|9.||Schiller, Henry J: 1 article (01/2010)|
|10.||Trempus, C S: 1 article (12/2000)|
01/01/1987 - "Similar chronic studies revealed that DMVC caused forestomach neoplasms in both rats and mice; neoplasms of the nasal and oral cavities were observed in rats but not in mice. "
12/01/2000 - "The present results confirm that DMVC is tumorigenic and that oral routes of administration can be used to rapidly elicit a transgene-associated tumor response in the forestomach of Tg.AC mice."
12/01/2000 - "In the National Toxicology Program 2-yr bioassay, DMVC induced tumors in the oral, nasal, and gastric epithelia of rats and mice. "
01/01/1987 - "This observation may explain the occurrence of tumors in the nasal and oral cavities of rats treated with DMVC but not in rats treated with CMP or in mice treated with DMVC in 2-year carcinogenicity studies. "
01/01/1987 - "A recent 2-year carcinogenicity study found that gavage administration of 3-chloro-2-methylpropene (CMP), containing 5% 1-chloro-2-methylpropene (dimethylvinyl chloride, DMVC), caused forestomach neoplasms in rats and mice. "
|2.||Wounds and Injuries (Trauma)
12/01/2000 - "The optimum papillomagenic dose of 100 mg/kg DMVC was established and administered for 5, 10, and 15/wk to investigate the kinetics of papilloma induction in Tg.AC mice. "
12/01/2000 - "DMVC was administered to 13- to14-wk-old Tg.AC mice by gavage at doses of 0, 50, 100, and 200 mg/kg five times a week for 20 wk. The forestomachs of DMVC-treated Tg.AC mice had an increasing number of papillomas, which were associated with an increase in the dose of DMVC. "
|2.||Cytidine Monophosphate (CMP)